The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

PD-1/PD-L1 inhibitors, malignant tumors, ASCO, ESMO, Immune Checkpoint Inhibitors, Gastrointestinal Cancers

Cancer drug innovation has significantly accelerated in the 21st century, with novel drug approvals and expenditures increasing notably. Assessment frameworks ASCO-VF and ESMO-MCBS were used to evaluate the clinical benefit of PD-1/PD-L1 inhibitors, finding that nearly half of the trials met "mea…

Feb 23^rd • 9 mins read

Report from American Society of Clinical Oncology Symposium 2020 and American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2021

ASCO, TNT, Gastrointestinal Cancer Symposium

Six out of 18 cancer drugs with accelerated approval still have indications on labeling and are recommended in guidelines despite not showing improvement in primary endpoints in post-approval trials. This issue highlights the imbalance between speed and evidence in the accelerated approval pathwa…

Aug 4^th • 13 mins read

Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers

PD-1/PD-L1 inhibitors, ESMO-MCBS, ASCO-VF, value, cost

Only a few treatment regimens showed clinical value in EC and CRC using ASCO-VF and ESMO-MCBS frameworks. Nivolumab met valuable threshold in resectable locally advanced EC/GEJC. 14 positive therapeutic regimens assessed; 11 negative regimens showed no improvement in QoL and were below the …

Apr 21^st • 13 mins read